Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms.
Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation.
Please click here to see the full interview: http://globalnews.ca/video/3628232/medical-and-recreational-marijuana
Halifax, Canada; July 2017: Panag Pharmaceuticals Inc., announces that Dr. Melanie Kelly, CSO of Panag and a professor of pharmacology and ophthalmology at Dalhousie University and Elizabeth Cairns, a PhD candidate studying pharmacology and neuroscience at Dalhousie University were interviewed Cassie Williams, Sameer Chhabra, of CBC News.
The interview stemmed from an op-ed article, published in the latest issue of the Canadian Medical Association Journal, co-authored by Dr. Kelly and Ms. Cairns.
In the article, Cairns and Kelly support a recommendation, proposed by the Liberal government’s task force on cannabis legalization and regulation, to keep the two so-called “streams” — medicinal and recreational — separate. This is in contrast to the Canadian Medical Association (CMA) who have publicly recommended just one stream once marijuana is legalized, arguing that more research must be conducted on cannabis before it should be approved for widespread medical use.
“With recreational cannabis, the focus is intoxication — that is not necessarily the case for medicinal cannabis,” said Cairns
The piece from Cairns and Kelly argues that a dual-stream approach would not only decrease the stigma surrounding medical cannabis, but would benefit patients in other ways including:
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of medical products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds.
Halifax, Nova Scotia. Panag Pharma Inc. announces that it has entered into a licensing agreement with Tetra Bio Pharma for its Topical ARx and Ocular products.
The Licensing Agreement provides for the continued development and commercialization of Panag’s unique products focused on providing patients with effective relief from pain.
Dr. Cheliak, Panag’s CEO notes that “combining the technical and clinical expertise of Panag with the regulatory and commercialization expertise of Tetra will accelerate the delivery of a new class of pain relief products to patients”.
“We are very pleased to announce this partnership with Panag as we work towards building an innovative product pipeline focused on cannabis,” said Andre Rancourt, CEO of Tetra Bio-Pharma.
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds.
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.TetraBioPharma.com.
Halifax, Nova Scotia. Panag Pharma Inc., announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/722,991 Entitled: COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN, a patent which protects its novel topical ocular product formulations.
Panag Pharma’s ocular formulation leverages a novel drug platform targeting the endocannabinoid system, a key modulator of pain and inflammation in the eye. Panag Pharma’s topical ocular formulation is the first technology of its kind that is directed at ocular inflammation and pain. Panag Pharma continues an aggressive preclinical research program with Phase 1 clinical trials planned for the fourth quarter of 2017.
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds. Learn more…
Halifax, Nova Scotia. Panag Pharma hosted a seminar for Health Care Professionals and the launch of a Regional Pilot Program to introduce Topical AOTC, a new generation pain and inflammation product.
Topical AOTC is a Health Canada approved natural product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis. Learn more about Topical AOTC
Clinical pain specialists, physiotherapists, chiropractors, sports medicine experts and podiatrists attended the information session. The pilot program will be running until March 17th 2017. During this time, Topical AOTC will be evaluated by a wide range of patients who will work closely with their health care provider. Following completion of the Regional Pilot program, Topical AOTC will be made available to patients through specialty clinics and via direct orders from Panag.
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds. Learn more…
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for Topical AOTC, a new generation topical formulation with a dual mechanism of action against pain. Topical AOTC is a natural health product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis.
Topical AOTC uses a novel technology targeting the endocannabinoid system and TRPV1 receptors, both known to play a key role in modulation of pain. There is no other similar product on the market. Panag Pharma will move forward with a regional launch of Topical AOTC to selected clinics in early 2017. Learn more about Topical AOTC
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds. Learn more…
Halifax, NS
Canada
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy